COVID-19
Biosimilars
Cataract Therapeutics
DME
Gene Therapy
Workplace
Ptosis
Optic Relief
Imaging
Geographic Atrophy
AMD
Presbyopia
Ocular Surface Disease
Practice Management
Pediatrics
Surgery
Therapeutics
Optometry
Retina
Cataract
Pharmacy
IOL
Dry Eye
Understanding Antibiotic Resistance
Refractive
Cornea
Glaucoma
OCT
Ocular Allergy
Clinical Diagnosis
Technology

Sustained-release implant promising for long-term IOP reduction

Name: Sustained-release implant promising for long-term IOP reduction
Uploaded: 2019-06-01T14:32:43Z
Description: E. Randy Craven, MD, shares results from a phase 1/2 study involving an intracameral bimatoprost sustained-release implant.

June 1, 2019

Julianne Mobilian

Article

Conferences|ASCRS

E. Randy Craven, MD, shares results from a phase 1/2 study involving an intracameral bimatoprost sustained-release implant.

E. Randy Craven, MD, discusses the pearls of his presentation, "Biodegradation of Intracameral Bimatoprost Sustained-Release Implant (Bimatoprost SR, Allergan) in a 24-Month, Phase 1/2 Study in Glaucoma Patients," which he shared at the annual 2019 ASCRS meeting in San Diego.